

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/060488 A1

- (51) International Patent Classification:
A61P 25/00 (2006.01) *C07K 14/01* (2006.01)
A61P 25/28 (2006.01) *C12N 15/85* (2006.01)
- (21) International Application Number:
PCT/US2021/045058
- (22) International Filing Date:
06 August 2021 (06.08.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/080,619 18 September 2020 (18.09.2020) US
- (71) Applicant: **OTHAIR PROTHENA LIMITED** [IE/IE];
77 Sir John Rogerson's Quay, Block C, Grand Canal Dock-
lands, Dublin 2, D02 VK60 (IE).
- (72) Inventors; and
(71) Applicants: **BARBOUR, Robin** [US/US]; 250 Normandy
Lane, Walnut Creek, CA 94598 (US). **KINNEY, Gene**
[US/US]; 2800 S. Ocean Blvd., Unit 14L/M, Boca Raton,
FL 33432 (US). **ZAGO, Wagner** [US/US]; 1291 Crestview
Drive, San Carlos, CA 94070 (US).
- (74) Agent: **GATTARI, Patrick, G.**; McDonnell Boehnen Hul-
bert & Berghoff LLP, 300 South Wacker Drive, Chicago,
IL 60606 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE




FIG. 3

(57) Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A β) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A β and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A β) peptide and an alpha-synuclein peptide.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))